We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution

This study has been terminated.
(Study objectives met)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01485822
First Posted: December 6, 2011
Last Update Posted: May 14, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Alcon Research
December 1, 2011
December 6, 2011
May 14, 2013
July 2004
February 2012   (Final data collection date for primary outcome measure)
Melanin Granule Count [ Time Frame: Day 1 ]
A trabecular meshwork tissue sample was collected by the investigator. The number of pigment granules was counted for three separate microscopic fields of view. Mean melanin granule count was calculated.
Melanin Granule Count [ Time Frame: Day 1 ]
A trabecular meshwork tissue sample will be collected by the investigator. The number of pigment granules will be counted for three separate microscopic fields of view. Mean melanin granule count will be calculated.
Complete list of historical versions of study NCT01485822 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution
A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution
The purpose of this study was to assess the pigmentation in the trabecular meshwork of patients who had been treated for at least 2 years with TRAVATAN compared with patients without exposure (or less than 1 month) to a prostaglandin analogue (PGA).
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients were identified and enrolled from 9 study centers in the US and 1 in Spain.
Open-angle Glaucoma
  • Procedure: Trabecular Meshwork Tissue Collection
    A minimum of two punches were used to remove tissue to form a sclerostomy. Tissue removed by the punch was collected for analysis. Alternatively, the tissue was collected by block excision of the meshwork with scissors at the time of sclerostomy.
  • Drug: Travoprost 0.004% ophthalmic solution
    Other Names:
    • TRAVATAN Z
    • TRAVATAN
  • TRAVATAN
    As prescribed by physician for the treatment of open-angle glaucoma and dosed for at least two years
    Interventions:
    • Procedure: Trabecular Meshwork Tissue Collection
    • Drug: Travoprost 0.004% ophthalmic solution
  • Treatment Naive
    No prior exposure (or less than 1 month) to any topical, ocular prostaglandin analogue
    Intervention: Procedure: Trabecular Meshwork Tissue Collection
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
88
February 2012
February 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of open-angle glaucoma without pseudoexfoliation or pigment dispersion component;
  • Either two or more years of dosing with Travatan, or no prior exposure (less than 1 month) to a topical ocular prostaglandin;
  • Requires a trabeculectomy;
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

  • Pseudoexfoliation or pigment dispersion;
  • History of chronic or recurrent severe inflammatory eye disease;
  • History of or current ocular infection or ocular inflammation within the past 3 months in either eye;
  • Greater than one month but less than two years of exposure to TRAVATAN;
  • Pregnant, breast-feeding, not using highly effective birth control;
  • Other protocol-defined exclusion criteria may apply.
Sexes Eligible for Study: All
50 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
 
NCT01485822
C-01-78
No
Not Provided
Not Provided
Alcon Research
Alcon Research
Not Provided
Study Director: Theresa Landry, PhD Alcon Research
Alcon Research
May 2013